Current Studies

Here is a list of some of our current studies. For additional studies, please visit RecruitMe.

  • The study is an outpatient treatment study of the safety and benefit of extended-release mixed amphetamine salt (Adderall-XR) in the treatment of individuals with cannabis use disorder and Attention Deficit/Hyperactivity Disorder (ADHD). The study is a 13-week trial and requires participants to come twice per week. The primary objective of the study is to determine the safety and effectiveness of Adderall-XR in decreasing marijuana use and in promoting a decrease in ADHD symptoms.
  • This study proposes to recruit patients with Opioid Use Disorder (OUD) seeking treatment into our program of a 5 day outpatient detoxification and naltrexone induction followed by a relapse-prevention treatment with Extended release-naltrexone (XR-NTX) for 8 weeks.
  • Principal Investigator

    Elias Dakwar, MD
    This 12-week free and confidential outpatient study is recruiting healthy adults who are currently seeking treatment for alcohol use. Participants will engage in twice-weekly clinic visits during which they will meet with a physician and complete measures with research assistants. Participants will also receive innovative, investigative medications twice throughout this trial (Weeks 2 and 5) to help facilitate their engagement in treatment.
  • Principal Investigator

    Elias Dakwar, MD
    This 12-week free and confidential outpatient study is recruiting healthy adults who are currently seeking treatment for cocaine use. Participants will engage in twice-weekly clinic visits during which they will have mindfulness-based therapy sessions, meet with a physician, and complete measures with research assistants. Participants will also receive innovative investigational medications twice throughout this trial (Weeks 1 and 5) to help facilitate their engagement in treatment.
  • Principal Investigator

    Elias Dakwar, MD
    This free and confidential study is recruiting healthy adults who are currently seeking treatment for opioid use (heroin, painkillers). Participants will be admitted into our inpatient unit for the first 3 to 5 days of the study. In addition to traditional medications used during detoxification, you will also receive innovative, investigative medications that may help with the transition onto Vivitrol (extended-release nalrexone). After discharge from the inpatient unit, participants will engage in twice-weekly outpatient visits for 12 weeks.
  • This study examines normal individual differences in the ways that the body and the brain respond to emotions, and the role of mitochondria in the mind-body connection. Mitochondria are small parts of each cell that make energy to keep us alive. Participants will be asked to come for a single two full-day visit, including two nights at a hotel next to the research center (Columbia University Medical Center). The study visit will include a blood draw, a medical exam, a cognitive testing session, questionnaires, an MRI scan, and at-home collection of saliva and stool samples the following week.
  • Children with Attention-Deficit/Hyperactivity Disorder (ADHD) are typically treated with two types of medications: stimulants and non-stimulants. These medications work in different ways to treat ADHD symptoms, but we do not fully understand the brain mechanisms underlying the medications' effects. This study will use MRI scanning to look at changes in the brain associated with medication treatment of ADHD in children.
  • Children with Attention-Deficit/Hyperactivity Disorder (ADHD) are typically treated with two types of medications: stimulants and non-stimulants. These medications work in different ways to treat ADHD symptoms, but we do not fully understand the brain mechanisms underlying the medications' effects. This study will use MRI scanning to look at changes in the brain associated with medication treatment of ADHD in children.
  • The purpose of this research study is to find out which antidepressants work best in individuals over the age of 60 years. We invite you to participate in this research study because you are 60+ years old have depression and your depression has not gotten better even after taking two or more medications.
  • Psilocybin is the active ingredient in some forms of psychedelic mushrooms. Its effects can include euphoria, visual hallucinations, changes in perception, a distorted sense of time and spiritual experiences. Adverse events can include headaches, rapid heart beat, increased blood pressure, nausea and panic attacks. All of these effects generally last minutes to hours, though perceptual changes occasionally recur to a lesser and lesser extent as they dissipate over several weeks.

Pages